Higher AML Complete Remission (CR) Rates and Significant Durability Reported with Additional Interim Subject Data May 15, 2024
FAILED TRIAL: Pivotal Ph 3 Study of Uproleselan in R/R AML patients did not meet primary endpoint of OS in the intent-to-treat population May 14, 2024
First Patients Dosed in Two Ph 1 Trials of REM-422 of Adenoid Cystic Carcinoma (ACC) and AML/MDS May 7, 2024
Positive Ph 2 Preliminary Data of SLS009 in R/R AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation at the Optimal Dose Level Announced May 7, 2024
Positive Recommendation of IDMC Following Completion of Enrollment in REGAL Ph 3 Study Announced May 1, 2024
Successful Completion of Higher Dose Second Cohort in Ph 1/1b Trial of BP1002 in R/R AML Patients April 23, 2024
EBMT 2024: Iomab-B Overcomes High-Risk TP53 Mutation Resulting in Significant OS Improvement in R/R AML Patients April 23, 2024
FDA Orphan Drug Designation and completion of FDA INTERACT meeting for BVX001 in the treatment of AML announced April 23, 2024
Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression April 16, 2024
Steering Committee Update Provided on Ph 3 REGAL Study with Positive Topline Data Announcement from Ph 2a Study of SLS009 in R/R AML April 2, 2024
Completion of Enrollment Announced in AUGMENT-101 Pivotal Trial Cohort of Patients with R/R mNPM1 AML April 2, 2024
Enrollment Initiated in 12-Patient Expansion Cohort of Voruciclib + Venetoclax in Ongoing Ph 1 Study April 2, 2024
Additional Positive Data announced from Ph 1 Part of BEXMAB Study in Both Higher-Risk HMA-Failed MDS and R/R AML March 26, 2024
First Patient dosed in the RIVER-52 Ph 2 Study of RVU120 for the Treatment of Patients with R/R AML and HR-MDS February 26, 2024
First Patient Dosed in Ph 1a Study with AVC-201 for the Treatment of R/R AML and other CD123 Heme Malignancies February 26, 2024
2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Ph 2b/3 announced January 31, 2024
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) January 23, 2024
